• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基质溶解素-1(MMP-3)对尿激酶型纤溶酶原激活剂的蛋白水解切割

Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3).

作者信息

Ugwu F, Van Hoef B, Bini A, Collen D, Lijnen H R

机构信息

Center for Molecular and Vascular Biology, University of Leuven, Belgium.

出版信息

Biochemistry. 1998 May 19;37(20):7231-6. doi: 10.1021/bi9728708.

DOI:10.1021/bi9728708
PMID:9585535
Abstract

Matrix metalloproteinase-3 (MMP-3, or stromelysin-1) specifically hydrolyzes the Glu143-Leu144 peptide bond in 45-kDa single-chain urokinase-type plasminogen activator (scu-PA) and in its two-chain (tcu-PA) derivative, yielding a 17-kDa NH2-terminal domain comprising the u-PA receptor (u-PAR) binding site and a 32-kDa COOH-terminal moiety containing the serine proteinase domain of u-PA. The conversion is completely abolished in the presence of the MMP inhibitors EDTA or 1,10-phenanthroline. Biospecific interaction analysis indicates that binding of MMP-3 occurs through the 32-kDa fragment. The 32-kDa fragment derived from scu-PA (scu-PA-32k) has a specific activity of </=500 IU/mg, but it can be activated with plasmin to a two-chain derivative (tcu-PA-32k) with a specific activity of 79 000 IU/mg. tcu-PA and tcu-PA-32k moieties derived from scu-PA-32k by plasmin or from tcu-PA by MMP-3 have comparable amidolytic activities toward the chromogenic substrate S-2444 (kcat/Km of 110 and 160 mM-1 s-1, respectively) and similar plasminogen activating activities in a coupled chromogenic substrate assay. Specific binding of the 17-kDa NH2-terminal domain to THP-1 monocytoid cells is completely abolished by competition with scu-PA but is not affected by scu-PA-32k (residual binding of 88 +/- 9% (mean +/- SEM; n = 3) with 25-fold molar excess). Thus, MMP-3 removes a functional NH2-terminal u-PAR-binding domain from u-PA without affecting its enzymatic properties.

摘要

基质金属蛋白酶-3(MMP-3,或基质溶解素-1)特异性水解45 kDa单链尿激酶型纤溶酶原激活剂(scu-PA)及其双链(tcu-PA)衍生物中的Glu143-Leu144肽键,产生一个包含u-PA受体(u-PAR)结合位点的17 kDa NH2末端结构域和一个包含u-PA丝氨酸蛋白酶结构域的32 kDa COOH末端部分。在MMP抑制剂EDTA或1,10-菲咯啉存在下,这种转化完全被消除。生物特异性相互作用分析表明,MMP-3的结合通过32 kDa片段发生。源自scu-PA的32 kDa片段(scu-PA-32k)的比活性≤500 IU/mg,但它可以被纤溶酶激活为比活性为79 000 IU/mg的双链衍生物(tcu-PA-32k)。通过纤溶酶从scu-PA-32k衍生的tcu-PA和tcu-PA-32k部分或通过MMP-3从tcu-PA衍生的部分对发色底物S-2444具有相当的酰胺水解活性(分别为110和160 mM-1 s-1的kcat/Km),并且在偶联发色底物测定中具有相似的纤溶酶原激活活性。17 kDa NH2末端结构域与THP-1单核细胞样细胞的特异性结合通过与scu-PA竞争而完全消除,但不受scu-PA-32k的影响(在25倍摩尔过量时残留结合为88±9%(平均值±标准误;n = 3))。因此,MMP-3从u-PA中去除了一个功能性的NH2末端u-PAR结合结构域,而不影响其酶学性质。

相似文献

1
Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3).基质溶解素-1(MMP-3)对尿激酶型纤溶酶原激活剂的蛋白水解切割
Biochemistry. 1998 May 19;37(20):7231-6. doi: 10.1021/bi9728708.
2
Modulation of cell-associated plasminogen activation by stromelysin-1 (MMP-3).基质溶解素-1(MMP-3)对细胞相关纤溶酶原激活的调节作用
Thromb Haemost. 1999 Sep;82(3):1127-31.
3
Native and non-glycosylated recombinant single-chain urokinase-type plasminogen activator are recognized by different receptor systems on rat parenchymal liver cells.天然和非糖基化重组单链尿激酶型纤溶酶原激活剂被大鼠肝实质细胞上不同的受体系统识别。
Thromb Haemost. 1995 Aug;74(2):722-9.
4
Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA).组织型纤溶酶原激活剂与尿激酶型纤溶酶原激活剂重组嵌合体(rt-PA/u-PA)的结构域缺失和/或重复突变体的特性分析
Thromb Haemost. 1990 Aug 13;64(1):53-60.
5
Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3).
Biochemistry. 1998 Apr 7;37(14):4699-702. doi: 10.1021/bi9731798.
6
Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.通过在纤溶酶切割位点融合获得的嵌合型(组织型/尿激酶型)纤溶酶原激活剂的特性。
Thromb Haemost. 1993 May 3;69(5):466-72.
7
Nerve growth factor-gamma activates soluble and receptor-bound single chain urokinase-type plasminogen activator.
J Biol Chem. 1993 Aug 5;268(22):16327-31.
8
Binding of human single chain urokinase to Chinese Hamster Ovary cells and cloning of hamster u-PAR.人单链尿激酶与中国仓鼠卵巢细胞的结合及仓鼠尿激酶型纤溶酶原激活物受体的克隆
Thromb Haemost. 1998 Jul;80(1):148-54.
9
Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.一种由纤维蛋白片段D - 二聚体特异性人源化单克隆抗体和截短的单链尿激酶组成的重组嵌合纤溶酶原激活剂的溶栓和药代动力学特性
Thromb Haemost. 1992 Aug 3;68(2):170-9.
10
Activation with plasmin of tow-chain urokinase-type plasminogen activator derived from single-chain urokinase-type plasminogen activator by treatment with thrombin.
Eur J Biochem. 1987 Dec 1;169(2):359-64. doi: 10.1111/j.1432-1033.1987.tb13620.x.

引用本文的文献

1
Reactive Oxygen Species in Venous Thrombosis.活性氧在静脉血栓形成中的作用
Int J Mol Sci. 2020 Mar 11;21(6):1918. doi: 10.3390/ijms21061918.
2
Matrix metalloproteinase-3 predicts clinical cardiovascular outcomes in patients with coronary artery disease: a 5 years cohort study.基质金属蛋白酶-3 可预测冠心病患者的临床心血管结局:一项 5 年队列研究。
Mol Biol Rep. 2019 Oct;46(5):4699-4707. doi: 10.1007/s11033-019-04914-4. Epub 2019 Jun 19.
3
Fibrinolytic PLGA nanoparticles for slow clot lysis within abdominal aortic aneurysms attenuate proteolytic loss of vascular elastic matrix.
用于腹主动脉瘤内缓慢血栓溶解的纤维蛋白溶解聚乳酸-羟基乙酸共聚物纳米颗粒可减轻血管弹性基质的蛋白水解损失。
Mater Sci Eng C Mater Biol Appl. 2016 Feb;59:145-156. doi: 10.1016/j.msec.2015.09.056. Epub 2015 Sep 16.
4
Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation.在血栓形成部位激活的红细胞靶向促尿激酶原酶促物介导的持续抗栓治疗。
Blood. 2010 Jun 24;115(25):5241-8. doi: 10.1182/blood-2010-01-261610. Epub 2010 Apr 21.
5
Pharmacoproteomics of a metalloproteinase hydroxamate inhibitor in breast cancer cells: dynamics of membrane type 1 matrix metalloproteinase-mediated membrane protein shedding.金属蛋白酶异羟肟酸酯抑制剂在乳腺癌细胞中的药物蛋白质组学:膜型1基质金属蛋白酶介导的膜蛋白脱落动力学
Mol Cell Biol. 2008 Aug;28(15):4896-914. doi: 10.1128/MCB.01775-07. Epub 2008 May 27.
6
Effect of cyclic tensile load on the regulation of the expression of matrix metalloproteases (MMPs -1, -3) and structural components in synovial cells.循环拉伸载荷对滑膜细胞中基质金属蛋白酶(MMP -1、-3)表达及结构成分调节的影响。
J Cell Mol Med. 2008 Dec;12(6A):2439-48. doi: 10.1111/j.1582-4934.2008.00245.x. Epub 2008 Jan 19.
7
Enhanced fibrinolysis in fingerstick blood samples: a possible role for matrix metalloproteinase-9.指尖血样本中纤维蛋白溶解增强:基质金属蛋白酶-9的潜在作用。
Thromb Res. 2007;120(5):773-8. doi: 10.1016/j.thromres.2006.12.018. Epub 2007 Apr 3.
8
Metalloproteinases and plasminogen activators in vessel remodeling.
Curr Hypertens Rep. 2003 Dec;5(6):466-72. doi: 10.1007/s11906-003-0054-5.
9
Proteases at the endometrial-trophoblast interface: their role in implantation.子宫内膜-滋养层界面的蛋白酶:它们在植入过程中的作用。
Rev Endocr Metab Disord. 2002 May;3(2):133-43. doi: 10.1023/a:1015407012559.